Pharmacological Evaluation of Antifungal in Chronic Pulmonary Aspergillosis

NCT05064605 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2022-06-28

No results posted yet for this study

Summary

At present, pulmonary diffusion and target antifungal concentrations for APC in patients with sarcoidosis or chronic obstructive pulmonary disease (COPD) are unknown.

Conditions

  • Chronic Respiratory Disease
  • Chronic Pulmonary Aspergillosis

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Yurdagül Yuzunhan, MD, PhD · Assistance Publique - Hôpitaux de Paris

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-01
Primary Completion
2022-10-01
Completion
2024-10-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05064605 on ClinicalTrials.gov